Soliqua Solostar (Insulin Glargine + Lixisenatide) Injection

Description

Description

This page contains brief details about the drug insulin glargine,lixisenatide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

The FDA approved Insulin glargine, Lixisenatide for medical use on 21st, Nov 2016 for Type 2 diabetes.

A 2022 study evaluated the efficacy of Insulin Glargine and Lixisenatide in adults with type 2 diabetes. The study found that Insulin Glargine and Lixisenatide significantly improved glycemic control by reducing HbA1c levels without causing weight gain. Additionally, the study reported a low risk of hypoglycemia.

Mechanism of Action of Insulin Glargine + Lixisenatide 

The Insulin glargine in the medicine, helps to lower the blood glucose level by replacing the insulin which is normally produced in our body.  The Lixisenatide is an GLP-1 agonist, which stimulates the release of insulin during the hyperglycemia (high blood glucose level).

Uses of Insulin Glargine + Lixisenatide 

Insulin glargine, Lixisenatide, is used to control blood sugar levels and elevate the production of insulin in the body. It also helps to slow down glucose absorption from foods. It aids in treating type 2 diabetes in adults and controls blood sugar when it becomes abnormal. If other medicines fail to treat or control high blood glucose levels, Insulin glargine, Lixisenatide can be given along with metformin and/or sodium-glucose co-transporter-2 (SGLT2) inhibitors.